

Glioblastoma multiforme and anaplastic astrocytoma p implications

Cancer

56, 1106-1111

DOI: 10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2

Citation Report

#	ARTICLE	IF	CITATIONS
1	Rate of Fat Uptake by Intestinal Lymphatics.. Experimental Biology and Medicine, 1961, 108, 278-282.	2.4	75
2	Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer, 1987, 59, 1617-1625.	4.1	629
3	Factors Determining Survival of Patients with Malignant Gliomas Diagnosed by Stereotactic Biopsy. Stereotactic and Functional Neurosurgery, 1987, 50, 183-187.	1.5	5
4	Malignant Supratentorial Gliomas in Childhood. Pediatric Neurosurgery, 1987, 13, 144-151.	0.7	11
5	Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.. Journal of Clinical Oncology, 1987, 5, 464-471.	1.6	24
6	Clinicopathologic correlations in the oligodendroglioma. Cancer, 1987, 59, 1345-1352.	4.1	137
7	Comparison of cytologic composition with microfluorometric DNA analysis of the glioblastoma multiforme and anaplastic astrocytoma. Cancer, 1987, 60, 59-65.	4.1	32
8	Supratentorial malignant gliomas in childhood: A review of fifty cases. Annals of Neurology, 1987, 22, 355-364.	5.3	93
9	Prognostic value of histologic factors in adult cerebral astrocytoma. Cancer, 1988, 61, 1386-1393.	4.1	49
10	Positron emission tomography in patients with glioma a predictor of prognosis. Cancer, 1988, 62, 1074-1078.	4.1	360
11	Grading of astrocytomas: A simple and reproducible method. Cancer, 1988, 62, 2152-2165.	4.1	838
12	Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. Journal of Neurosurgery, 1988, 68, 698-704.	1.6	397
13	Correlation of DNA Content and Histology in Prognosis of Astrocytomas. American Journal of Clinical Pathology, 1988, 90, 289-293.	0.7	42
14	Case 26-1988. New England Journal of Medicine, 1988, 318, 1742-1750.	27.0	9
15	Incidence and Survival of Brain Tumors: A Population-Based Study. Tumori, 1988, 74, 243-252.	1.1	25
16	High-grade cerebral neuroblastoma: a case study. Medical Journal of Australia, 1989, 150, 505-507.	1.7	5
17	Supratentorial anaplastic gliomas in adults. Journal of Neurosurgery, 1989, 71, 487-493.	1.6	266
18	Juvenile pilocytic astrocytomas: CT and MR characteristics. American Journal of Roentgenology, 1989, 152, 1263-1270.	2.2	137

#	ARTICLE	IF	CITATIONS
19	Lack of histopathological correlation of malignant ependymomas with postoperative survival. Journal of Neurosurgery, 1989, 70, 31-36.	1.6	173
20	Radiation therapy in the management of low-grade supratentorial astrocytomas. Journal of Neurosurgery, 1989, 70, 853-861.	1.6	301
21	Craniocerebral epidermoids and dermoids. Acta Neurochirurgica, 1989, 97, 1-16.	1.7	166
22	Malignant monstrocellular brain tumours. Acta Neurochirurgica, 1989, 97, 17-25.	1.7	52
23	Supratentorial astrocytic tumours of childhood: A clinicopathologic study of 41 cases. Acta Neurochirurgica, 1989, 101, 3-8.	1.7	17
24	PROGNOSIS IN MALIGNANT GLIOMA: A RETROSPECTIVE STUDY OF BIOPSY SPECIMENS BY FLOW CYTOMETRY. Neuropathology and Applied Neurobiology, 1989, 15, 331-338.	3.2	16
25	Patterns of proto-oncogene expression in human glioma cell lines. Journal of Neuroscience Research, 1989, 24, 97-106.	2.9	37
26	Chemotherapy for malignant gliomas?. Annals of Neurology, 1989, 25, 88-89.	5.3	6
27	Selection bias in clinical trails of anaplastic glioma. Annals of Neurology, 1989, 26, 531-534.	5.3	58
28	Hypofractionated radiation therapy and concurrent cisplatin in malignant cerebral gliomas. Rapid palliation in low performance status patients. Cancer, 1989, 64, 816-820.	4.1	16
29	Adjuvant intraarterial chemotherapy with nimustine in the management of world health organization grade IV gliomas of the brain. Experience at the department of neurosurgery of Düsseldorf university. Cancer, 1989, 64, 1984-1994.	4.1	39
30	The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. Journal of Neuro-Oncology, 1989, 7, 165-177.	2.9	348
31	Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. International Journal of Radiation Oncology Biology Physics, 1989, 16, 1389-1396.	0.8	451
32	Mitotic recombination of chromosome 17 in astrocytomas.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2858-2862.	7.1	253
33	Long-Term Survival after Malignant Glioma a Clinical and Histopathological Study on the Accuracy of the Diagnosis in a Population-Based Cancer Register. Acta Oncologica, 1990, 29, 875-878.	1.8	23
34	Genetic and Epigenetic Losses of Heterozygosity in Cancer Predisposition and Progression. Advances in Cancer Research, 1990, 54, 25-62.	5.0	71
35	Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathology and Applied Neurobiology, 1990, 16, 123-133.	3.2	83
36	Adult supratentorial tumors. Seminars in Roentgenology, 1990, 25, 130-154.	0.6	33

#	ARTICLE	IF	CITATIONS
37	Radiotherapy for high grade gliomas. International Journal of Radiation Oncology Biology Physics, 1990, 18, 793-803.	0.8	69
38	Dietary <i>Chlorella pyrenoidosa</i> for patients with malignant glioma: Effects on immunocompetence, quality of life, and survival. Phytotherapy Research, 1990, 4, 220-231.	5.8	26
39	Effects of treatment on long-term survivors with malignant astrocytomas. Annals of Neurology, 1990, 28, 818-822.	5.3	253
40	Malignant astrocytic gliomas in children. Cancer, 1990, 65, 2771-2778.	4.1	80
41	Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas <i>in vivo</i> . Preliminary observations on tumor grading. NMR in Biomedicine, 1990, 3, 184-189.	2.8	119
42	Phase II trial of <i>Serratia marcescens</i> extract in recurrent malignant astrocytoma.. Journal of Clinical Oncology, 1990, 8, 1408-1418.	1.6	21
43	Malignant astrocytoma in South Australia: treatment and case survival. Medical Journal of Australia, 1990, 153, 250-254.	1.7	8
44	A Cluster Classification for Histologic Diagnoses of CNS Tumors in an Epidemiologic Study. Neuroepidemiology, 1990, 9, 2-16.	2.3	14
45	Descriptive Epidemiology of Malignant Brain Tumors in the Swiss Canton of Vaud. Neuroepidemiology, 1990, 9, 135-142.	2.3	15
46	Indications for Surgery in the Management of Gliomas. Advances and Technical Standards in Neurosurgery, 1990, 17, 189-234.	0.5	27
47	Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8602-8606.	7.1	535
48	The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. Journal of Neurosurgery, 1990, 73, 331-344.	1.6	274
49	Anaplastic astrocytoma and glioblastoma: pion irradiation with the dynamic conformation technique at the Swiss Institute for Nuclear Research (SIN). Radiotherapy and Oncology, 1990, 17, 37-46.	0.6	12
50	Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases. Radiotherapy and Oncology, 1990, 18, 9-17.	0.6	68
51	Brain Tumors. New England Journal of Medicine, 1991, 324, 1555-1564.	27.0	193
52	Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiotherapy and Oncology, 1991, 20, 99-110.	0.6	128
53	Undifferenzierte Gliome: Ergebnisse unter Strahlentherapie und Razoxan. Oncology Research and Treatment, 1991, 14, 507-513.	1.2	1
54	Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance. British Journal of Cancer, 1991, 63, 553-560.	6.4	42

#	ARTICLE	IF	CITATIONS
55	Cancer diagnosis by molecular genetic probes: The present and the promise. <i>Annals of Oncology</i> , 1991, 2, 629-633.	1.2	1
56	Pediatric brain tumors. <i>Current Problems in Pediatrics</i> , 1991, 21, 129-173.	1.1	18
57	Evaluation of bromodeoxyuridine in glioblastoma multiforme: A A Northern California cancer center phase II study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 21, 709-714.	0.8	93
58	Molecular genetics of human cancer predisposition and progression. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1991, 247, 199-202.	1.0	41
59	Histopathology of astrocytomas: Grading, patterns of spread, and correlation with modern imaging modalities. <i>Seminars in Radiation Oncology</i> , 1991, 1, 2-9.	2.2	6
60	The management of malignant gliomas with radiation therapy: Therapeutic results and research strategies. <i>Seminars in Radiation Oncology</i> , 1991, 1, 32-49.	2.2	20
61	Nucleolar organizer regions and postoperative survival in glioblastoma multiforme. <i>Neuropathology and Applied Neurobiology</i> , 1991, 17, 17-20.	3.2	8
62	Genetics of the malignant progression of astrocytoma. <i>Journal of Cellular Biochemistry</i> , 1991, 46, 3-8.	2.6	37
63	Dna ploidy and cell-cycle analysis: Tools for assessment of cancer prognosis. <i>Journal of Clinical Laboratory Analysis</i> , 1991, 5, 422-438.	2.1	5
64	Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults. <i>Cancer</i> , 1991, 67, 1629-1634.	4.1	41
65	Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases. <i>Cancer</i> , 1991, 67, 2342-2349.	4.1	166
66	Proliferating cell nuclear antigen expression in central nervous system neoplasms. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1991, 419, 417-423.	1.4	102
67	Stereological estimates of nuclear volume and other quantitative variables in supratentorial brain tumors Practical technique and use in prognostic evaluation. <i>Journal of Neuro-Oncology</i> , 1991, 10, 253-62.	2.9	6
68	Correlates of survival and the Daumas-Duport grading system for astrocytomas. <i>Journal of Neurosurgery</i> , 1991, 74, 27-37.	1.6	140
69	Gemistocytic astrocytomas: a reappraisal. <i>Journal of Neurosurgery</i> , 1991, 74, 399-406.	1.6	131
70	Case 23-1991. <i>New England Journal of Medicine</i> , 1991, 324, 1651-1659.	27.0	1
71	Cytokines and immunoregulatory molecules in malignant glial neoplasms. <i>Journal of Neurosurgery</i> , 1992, 77, 265-273.	1.6	78
72	Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 1992, 77, 295-301.	1.6	185

#	ARTICLE	IF	CITATIONS
73	Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4309-4313.	7.1	556
74	mRNA coding for neurotransmitter receptors in a human astrocytoma.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3399-3403.	7.1	25
75	Molecular Genetic Characterization of Cns Tumor Oncogenesis. Advances in Cancer Research, 1992, 58, 121-142.	5.0	18
76	Clinicopathological evaluation of 78 astrocytomas in Taiwan with emphasis on a simple grading system. Journal of Neuro-Oncology, 1992, 13, 265-76.	2.9	6
77	Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. Journal of Neuro-Oncology, 1992, 12, 219-227.	2.9	109
78	Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy. Journal of Neuro-Oncology, 1992, 13, 131-5.	2.9	19
79	Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status. Journal of Neuro-Oncology, 1992, 13, 177-81.	2.9	56
80	Diffuse ?fibrillary? astrocytomas: correlation of MRI features with histopathologic parameters and tumor grade. Neuroradiology, 1992, 34, 173-178.	2.2	44
81	Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359, 843-845.	27.8	4,254
82	An overview of principles for classifying brain tumors. Molecular and Chemical Neuropathology, 1992, 17, 103-120.	1.0	14
83	Grading of brain tumours. The British experience. Neurosurgical Review, 1992, 15, 7-11.	2.4	6
84	Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989. International Journal of Radiation Oncology Biology Physics, 1992, 23, 3-8.	0.8	115
85	Loss of constitutional heterozygosity in human astrocytomas. Acta Neurochirurgica, 1992, 117, 172-177.	1.7	4
86	Studies of human tumors by MRS: A review. NMR in Biomedicine, 1992, 5, 303-324.	2.8	525
87	Histopathologic grading and DNA ploidy in relation to survival among 206 adult astrocytic tumor patients. Cancer, 1992, 70, 538-546.	4.1	53
88	Accumulation of genetic defects during astrocytoma progression. Cancer, 1992, 70, 1788-1793.	4.1	51
89	Regional heterogeneity in the DNA content of human gliomas. Cancer, 1993, 72, 3052-3060.	4.1	66
90	Endothelial cell marker PAL-E reactivity in brain tumor, developing brain, and brain disease. Cancer, 1993, 72, 3061-3067.	4.1	31

#	ARTICLE	IF	CITATIONS
91	Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics, 1993, 25, 243-249.	0.8	116
92	Genetics of cancer predisposition and progression. The Clinical Investigator, 1993, 71, 488-502.	0.6	13
93	Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Human Genetics, 1993, 92, 169-74.	3.8	115
94	Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. Journal of Neuro-Oncology, 1993, 15, 9-17.	2.9	5
95	Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro. Journal of Neuro-Oncology, 1993, 18, 151-161.	2.9	24
96	Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) Lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. Journal of Neuro-Oncology, 1993, 15, 141-155.	2.9	37
97	Expression of Gangliosides GD3 and 3'-isoLM1 in Autopsy Brains from Patients with Malignant Tumors. Journal of Neurochemistry, 1993, 60, 99-105.	3.9	43
98	Assessment of nuclear size, nuclear DNA content and proliferation index in stereotaxic biopsies from brain tumours. Neuropathology and Applied Neurobiology, 1993, 19, 507-518.	3.2	11
99	Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). Journal of Neuro-Oncology, 1993, 16, 93-104.	2.9	61
100	Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. Journal of Neurosurgery, 1993, 78, 762-766.	1.6	201
101	Resection, biopsy, and survival in malignant glial neoplasms. Journal of Neurosurgery, 1993, 78, 767-775.	1.6	326
102	The chemotherapy of adult primary brain tumors. Cancer Treatment Reviews, 1993, 19, 261-281.	7.7	24
103	Relationship between proliferative activity and ploidy level in a series of 530 human brain tumors, including astrocytomas, meningiomas, schwannomas, and metastases. Human Pathology, 1993, 24, 329-335.	2.0	45
104	Computed tomography and histologic limits in glial neoplasms: Tumor types and selection for volumetric resection. World Neurosurgery, 1993, 39, 458-465.	1.3	37
105	Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. Brain Pathology, 1993, 3, 19-26.	4.1	597
106	Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. Journal of Neurosurgery, 1993, 79, 533-536.	1.6	226
107	Central nervous system gangliogliomas. Journal of Neurosurgery, 1993, 79, 859-866.	1.6	200
108	Human-specific c-neu proto-oncogene protein overexpression in human malignant astrocytomas before and after xenografting. Journal of Neurosurgery, 1993, 78, 240-251.	1.6	24

#	ARTICLE	IF	CITATIONS
109	A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. <i>Journal of Neurosurgery</i> , 1993, 78, 909-914.	1.6	143
110	Effect of Chemoradiotherapy Using ACNU, Vincristine, and Nicardipine with High-dose Irradiation on Malignant Astrocytomas. <i>Neurologia Medico-Chirurgica</i> , 1993, 33, 295-299.	2.2	3
111	Receptor Tyrosine Kinase Expression in Astrocytic Lesions. <i>Neurosurgery</i> , 1993, 33, 106-115.	1.1	25
112	Low-Grade Astrocytomas May Arise from Different Astrocyte Lineages. <i>Neurosurgery</i> , 1993, 33, 627-632.	1.1	35
113	Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma.. <i>Journal of Clinical Oncology</i> , 1993, 11, 1746-1750.	1.6	10
114	Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.. <i>Journal of Clinical Oncology</i> , 1993, 11, 77-83.	1.6	39
115	Grading Astrocytomas. <i>Neurosurgery Clinics of North America</i> , 1994, 5, 35-41.	1.7	3
116	Prognostic Significance of Ki-67 Proliferation Index in Supratentorial Fibrillary Astrocytic Neoplasms. <i>Neurosurgery</i> , 1994, 34, 674-679.	1.1	75
117	Histological Characteristics and Expression of Acidic and Basic Fibroblast Growth Factor Genes in Intracerebral Xenogeneic Transplants of Human Glioma Cells. <i>Neurosurgery</i> , 1994, 34, 136-143.	1.1	38
118	Long-Term Survival in Patients with Malignant Astrocytoma. <i>Neurosurgery</i> , 1994, 34, 213-220.	1.1	124
119	The Limited Value of Cytoreductive Surgery in Elderly Patients with Malignant Gliomas. <i>Neurosurgery</i> , 1994, 34, 62-67.	1.1	102
120	Proliferating Cell Nuclear Antigen (PCNA) in Low-Grade Astrocytomas: Its Prognostic Significance. <i>Tumori</i> , 1994, 80, 295-300.	1.1	20
121	Prognostic Significance of Flow Cytometry Deoxyribonucleic Acid Analysis of Human Oligodendrogliomas. <i>Neurosurgery</i> , 1994, 34, 680-687.	1.1	22
122	The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas. <i>Journal of Neuro-Oncology</i> , 1994, 19, 113-122.	2.9	14
123	Intra-operative radiation therapy for malignant brain tumours: Rationale, method, and treatment results of cerebral glioblastomas. <i>Acta Neurochirurgica</i> , 1994, 131, 80-90.	1.7	34
124	Proteins of the intermediate filament cytoskeleton as markers for astrocytes and human astrocytomas. <i>Molecular and Chemical Neuropathology</i> , 1994, 21, 155-176.	1.0	47
125	Assessment of the pathological grade of astrocytic gliomas using an MRI score. <i>Neuroradiology</i> , 1994, 36, 308-310.	2.2	76
126	The basis for current treatment recommendations for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 1994, 20, 111-120.	2.9	118

#	ARTICLE	IF	CITATIONS
127	Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults. Journal of Neuro-Oncology, 1994, 19, 227-237.	2.9	12
128	Patterns of reactivity with anti-glycolipid antibodies in human primary brain tumors. Journal of Neuroscience Research, 1994, 39, 148-158.	2.9	14
129	Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer, 1994, 74, 920-927.	4.1	79
130	Chromosome analysis of brain tumors in childhood. Genes Chromosomes and Cancer, 1994, 11, 205-215.	2.8	43
131	A cytogenetic study of 19 recurrent gliomas. Cancer Genetics and Cytogenetics, 1994, 76, 85-92.	1.0	22
133	Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiotherapy and Oncology, 1994, 30, 146-149.	0.6	126
134	Neutron Capture Therapy of a Rat Glioma Using Boronophenylalanine as a Capture Agent. Radiation Research, 1994, 137, 44.	1.5	20
135	Proliferating Cell Nuclear Antigen Expression in the Survival of Astrocytoma Patients. Canadian Journal of Neurological Sciences, 1994, 21, 306-310.	0.5	14
136	Prognostic scoring in adult astrocytic tumors using patient age, histopathological grade, and DNA histogram type. Journal of Neurosurgery, 1994, 80, 877-883.	1.6	38
137	Prognostic Significance of Flow Cytometry Deoxyribonucleic Acid Analysis of Human Astrocytomas. Neurosurgery, 1994, 35, 119-126.	1.1	31
138	Low-grade Glial Tumors in Basal Ganglia and Thalamus. Neurosurgery, 1994, 35, 817-821.	1.1	55
139	Etiology of Brain Tumors in Adults. Epidemiologic Reviews, 1995, 17, 382-414.	3.5	234
140	Glioblastoma Cells Do Not Intravasate into Blood Vessels. Neurosurgery, 1995, 36, 124-132.	1.1	118
141	Glioblastoma Cells Do Not Intravasate into Blood Vessels. Neurosurgery, 1995, 36, 124-132.	1.1	4
142	Correlation of ganglioside patterns of primary brain tumors with survival. Cancer, 1995, 75, 851-859.	4.1	22
143	Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer, 1995, 75, 2727-2731.	4.1	169
144	Clinicopathologic features of primary and postirradiation cerebral gliosarcoma. Cancer, 1995, 75, 2910-2918.	4.1	118
145	Central pathology review in clinical trials for patients with malignant glioma. A report of radiation therapy oncology group 83-02. Cancer, 1995, 76, 307-313.	4.1	84

#	ARTICLE	IF	CITATIONS
146	Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. <i>Cancer</i> , 1995, 76, 840-852.	4.1	172
147	Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas. <i>International Journal of Cancer</i> , 1995, 60, 478-481.	5.1	47
148	Relationship between DNA ploidy level and tumor sociology behavior in 12 nervous cell lines. <i>Cytometry</i> , 1995, 20, 118-126.	1.8	10
149	Tumor antigens in astrocytic gliomas. <i>Glia</i> , 1995, 15, 244-256.	4.9	110
150	Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells in vitro. <i>Molecular and Chemical Neuropathology</i> , 1995, 24, 121-135.	1.0	28
151	Response predictors for high-grade gliomas given definitive irradiation. <i>Radiation Oncology Investigations</i> , 1995, 3, 133-140.	0.9	0
152	Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 75-83.	0.8	75
153	MR classification of brain gliomas: Value of magnetization transfer and conventional imaging. <i>Magnetic Resonance Imaging</i> , 1995, 13, 501-511.	1.8	45
154	Heterogeneity, polyploidy, aneusomy, and 9p deletion in human glioblastoma multiforme. <i>Cancer Genetics and Cytogenetics</i> , 1995, 83, 127-135.	1.0	17
155	Effectiveness of Early Chemotherapy Treatment in Anaplastic Astrocytoma Patients. <i>Tumori</i> , 1995, 81, 424-428.	1.1	1
156	Aberrant p53 Expression Does Not Correlate with the Prognosis in Anaplastic Astrocytoma. <i>Neurosurgery</i> , 1995, 37, 246-254.	1.1	33
157	Adhesion of Human Glioma Cell Lines to Fibronectin, Laminin, Vitronectin and Collagen I Is Modulated by Gangliosides in vitro. <i>Cell Adhesion and Communication</i> , 1995, 3, 27-43.	1.7	41
158	Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 59, 413-419.	1.9	52
159	THE CHARACTERIZATION OF NUCLEAR-DNA CONTENT, THE PROLIFERATIVE ACTIVITY AND THE IMMUNOHISTOCHEMICAL EXPRESSION OF GFAP, VIM, LEU-7, S-100, P53 AND CATHEPSIN-D IN HUMAN GLIOBLASTOMA MULTIFORMES (HGBMS) VERSUS HUMAN GBM CELL-LINES GRAFTED INTO THE BRAINS OF NUDE-MICE. <i>International Journal of Oncology</i> , 1995, 6, 473-81.	3.3	11
160	THE COMBINED USE OF THE DECISION TREE TECHNIQUE AND THE COMPUTER-ASSISTED MICROSCOPE ANALYSIS OF FEULGEN-STAINED NUCLEI AS AN AID FOR ASTROCYTIC TUMOR AGGRESSIVENESS CHARACTERIZATION. <i>International Journal of Oncology</i> , 1995, 7, 183-189.	3.3	1
161	Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. <i>Journal of Neurosurgery</i> , 1995, 82, 523-529.	1.6	67
162	Lymphoplasmacyte-rich meningioma in a child. <i>Journal of Neurosurgery</i> , 1995, 83, 1075-1079.	1.6	23
163	Performance of sulphhydryl boron hydride in patients with grade III and IV astrocytoma: a basis for boron neutron capture therapy. <i>Journal of Neurosurgery</i> , 1995, 83, 79-85.	1.6	25

#	ARTICLE	IF	CITATIONS
164	Assessment of brain tumor cell motility in vivo and in vitro. Journal of Neurosurgery, 1995, 82, 615-622.	1.6	125
165	Classification of gliomas. Current Diagnostic Pathology, 1995, 2, 175-180.	0.4	1
166	Supratentorial glioblastoma: Neuroradiological findings and survival after surgery and radiotherapy. Neuroradiology, 1996, 38, S26-S30.	2.2	22
167	Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 524-529.	2.1	19
168	A Phase I Study of an Anti-epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant Gliomas. Neurosurgery, 1996, 39, 478-483.	1.1	74
169	Effects of Iodine-125 Brachytherapy on the Proliferative Capacity and Histopathological Features of Glioblastoma Recurring after Initial Therapy<subtitle>Converting K08 and K23 to R01 Awards</subtitle>. Neurosurgery, 1996, , .	1.1	0
170	Molecular Biology of Malignant Degeneration of Astrocytoma. Pediatric Neurosurgery, 1996, 24, 41-49.	0.7	16
171	Immune infiltrates and cytokines in gliomas. Acta Neurochirurgica, 1996, 138, 50-56.	1.7	67
172	Cell kinetic analysis in recurrent neuro-epithelial tumours. Acta Neurochirurgica, 1996, 138, 1036-1041.	1.7	0
173	Pathology of brain tumours: the current state of diagnostic practice. Neuropathology and Applied Neurobiology, 1996, 22, 407-412.	3.2	2
174	Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer, 1996, 77, 362-372.	4.1	419
175	Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. , 1996, 77, 373-380.		141
176	Necrosis as a prognostic factor in glioblastoma multiforme. , 1996, 77, 1161-1166.		124
177	Regional glucose metabolism and histopathology of gliomas: A study based on positron emission tomography-guided stereotactic biopsy. Cancer, 1996, 78, 1098-1106.	4.1	116
178	Epidermal growth factor receptor: An independent predictor of survival in astrocytic tumors given definitive irradiation. International Journal of Radiation Oncology Biology Physics, 1996, 34, 809-815.	0.8	83
179	Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1251-1261.	0.8	129
180	Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology, 1996, 28, 521-528.	2.9	52
181	Prognostic significance of preoperative MRI scans in glioblastoma multiforme. Journal of Neuro-Oncology, 1996, 27, 65-73.	2.9	227

#	ARTICLE	IF	CITATIONS
182	A grading study of gliomas using computer aided malignancy classification and histologic morphometry. Journal of Neuro-Oncology, 1996, 27, 75-85.	2.9	8
183	Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. Journal of Neuro-Oncology, 1996, 30, 61-9.	2.9	159
184	The expanding role of chemotherapy for pediatric supratentorial malignant gliomas. Journal of Neuro-Oncology, 1996, 28, 185-91.	2.9	5
185	Management of primary malignant brain tumours.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 2-5.	1.9	23
186	Radioimmunotherapy in the treatment of malignant astrocytomas. Drug Delivery, 1996, 3, 87-92.	5.7	0
187	Intracranial Tumors. Veterinary Clinics of North America - Small Animal Practice, 1996, 26, 759-777.	1.5	46
188	Intramedullary spinal cord tumors in children under the age of 3 years. Journal of Neurosurgery, 1996, 85, 1036-1043.	1.6	184
189	Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. Journal of Neurosurgery, 1996, 84, 449-458.	1.6	332
190	Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P16ink4 homozygous deletions and CDK4 gene amplifications. Journal of Neurosurgery, 1996, 84, 1020-1023.	1.6	13
191	Nearest-neighbor classification for identification of aggressive versus nonaggressive low-grade astrocytic tumors by means of image cytometry-generated variables. Journal of Neurosurgery, 1997, 86, 532-537.	1.6	23
193	Comparison of accelerated hyperfractionated radiotherapy and conventional radiotherapy for supratentorial malignant glioma. Japanese Journal of Clinical Oncology, 1997, 27, 31-36.	1.3	23
194	Biodistribution of 125I-MAb 425 in a Human Glioma Xenograft Model: Effect of Chloroquine. Hybridoma, 1997, 16, 93-100.	0.6	7
195	Primary Brain Cancer in Adults and the Use of Common Household Appliances: A Case-Control Study. Reviews on Environmental Health, 1997, 12, 59-62.	2.4	2
196	The Combined Determination of Proliferative Activity and Cell Density in the Prognosis of Adult Patients With Supratentorial High-Grade Astrocytic Tumors. American Journal of Clinical Pathology, 1997, 107, 321-331.	0.7	42
197	Recognition and Management of Gliomas. Drugs, 1997, 53, 235-244.	10.9	42
198	Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. Journal of Neurosurgery, 1997, 86, 121-130.	1.6	95
200	The Prognostic Significance of Ki-67 Labeling Indices for Oligodendrogliomas. Neurosurgery, 1997, 41, 878-885.	1.1	108
201	A Molecular Genetic Model of Astrocytoma Histopathology. Brain Pathology, 1997, 7, 755-764.	4.1	176

#	ARTICLE	IF	CITATIONS
202	Supratentorial diffuse astrocytic tumours: proposal of an MRI classification. European Radiology, 1997, 7, 395-399.	4.5	61
203	Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. Journal of Neuro-Oncology, 1997, 34, 179-185.	2.9	25
204	Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study. Journal of Neuro-Oncology, 1997, 32, 45-55.	2.9	19
205	Lectin histochemistry of astrocytic tumors and in vitro characterization of lectin-induced modifications on the proliferation of the SW1088, U373 and U87 human astrocytic cell lines. Journal of Neuro-Oncology, 1997, 34, 111-122.	2.9	4
206	Mitogens as motogens. , 1997, 35, 249-257.		61
207	Title is missing!. Wireless Networks, 1997, 3, 463-469.	3.0	24
208	Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharmaceutical Research, 1997, 14, 992-998.	3.5	67
209	Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer, 1997, 79, 1381-1393.	4.1	496
210	Long-term survival in patients with supratentorial glioblastoma. Journal of Neuro-Oncology, 1998, 36, 61-64.	2.9	46
211	Single-Fraction Radiosurgery for Primary and Recurrent Malignant Gliomas. Journal of Radiosurgery, 1998, 1, 155-168.	0.1	8
212	Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas. Neuropathology, 1998, 18, 145-153.	1.2	2
213	IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2. Journal of Neuroimmunology, 1998, 92, 50-59.	2.3	22
214	Mitosis identification in diffuse gliomas. Cancer, 1998, 82, 1550-1555.	4.1	22
215	Genetic sub-types of human malignant astrocytoma correlate with survival. International Journal of Cancer, 1998, 79, 159-165.	5.1	54
216	Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. , 1998, 11, 192-200.		91
217	Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. , 1998, 21, 195-206.		74
218	NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magnetic Resonance in Medicine, 1998, 40, 793-799.	3.0	331
219	Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathologica, 1998, 96, 322-328.	7.7	83

#	ARTICLE	IF	CITATIONS
220	Determination of growth fraction and cell density to evaluate the potential growth of human oligodendroglial and astrocytic tumours. Journal of Cancer Research and Clinical Oncology, 1998, 124, 427-434.	2.5	2
221	Clinical Outcome of Supratentorial Astrocytoma WHO Grade II. Acta Neurochirurgica, 1998, 140, 1213-1222.	1.7	79
222	Long-term survival in a patient with supratentorial glioblastoma: clinical considerations. Italian Journal of Neurological Sciences, 1998, 19, 221-224.	0.1	8
223	Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology, 1998, 40, 150-153.	2.2	55
224	Efficacy of radiotherapy for malignant gliomas in elderly patients. International Journal of Radiation Oncology Biology Physics, 1998, 42, 977-980.	0.8	64
225	Treatment by a specialist surgical neuro-oncologist does not provide any survival advantage for patients with a malignant glioma. British Journal of Neurosurgery, 1998, 12, 29-32.	0.8	10
226	Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 747-750.	1.9	23
227	Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling. Journal of Clinical Pathology, 1998, 51, 284-293.	2.0	33
228	Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas.. American Journal of Roentgenology, 1998, 171, 1479-1486.	2.2	426
229	The costs of managing patients with malignant glioma at a neuro-oncology clinic*. British Journal of Neurosurgery, 1998, 12, 118-122.	0.8	27
230	Neurosurgical considerations in supratentorial low-grade gliomas: experience with 175 patients. Neurosurgical Focus, 1998, 4, E6.	2.3	15
231	Autopsy Findings in a Long-term Survivor With Glioblastoma Multiforme â€”Case Reportâ€”. Neurologia Medico-Chirurgica, 1998, 38, 95-99.	2.2	4
232	Treatment of Malignant Gliomas: A New Approach. Tumori, 1998, 84, 529-533.	1.1	2
233	KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma. Journal of Clinical Oncology, 1999, 17, 2579-2579.	1.6	16
234	New Treatment Strategies for Malignant Gliomas. Oncologist, 1999, 4, 209-224.	3.7	147
235	A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neuro-Oncology, 1999, 1, 169-176.	1.2	29
236	Prognostic Significance of Histologic and Cytometric Factors in Supratentorial Astrocytomas. International Journal of Surgical Pathology, 1999, 7, 205-215.	0.8	0
237	Glial Neoplasms: Dynamic Contrast-enhanced T2*-weighted MR Imaging. Radiology, 1999, 211, 791-798.	7.3	583

#	ARTICLE	IF	CITATIONS
238	Reirradiation and lomustine in patients with relapsed high-grade gliomas. International Journal of Radiation Oncology Biology Physics, 1999, 43, 789-793.	0.8	63
239	The role of surgery in low grade gliomas. , 1999, 42, 259-269.		30
240	The role of stereotactic biopsy in the management of gliomas. Journal of Neuro-Oncology, 1999, 42, 205-213.	2.9	43
241	Postoperative radiotherapy for supratentorial malignant gliomas. Journal of Neuro-Oncology, 1999, 42, 183-187.	2.9	6
242	Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. Journal of Neuro-Oncology, 1999, 45, 159-165.	2.9	17
243	A correlative study of gliomas using In vivo bromodeoxyuridine labeling index and computer-aided malignancy grading. Pathology and Oncology Research, 1999, 5, 134-141.	1.9	5
244	Cerebral neoplasms in adults. Seminars in Roentgenology, 1999, 34, 102-122.	0.6	9
245	Scatter factor/hepatocyte growth factor gene transfer increases rat blood-brain glioma barrier permeability. Brain Research, 1999, 833, 173-180.	2.2	16
246	Laminin expression by glial fibrillary acidic protein positive cells in human gliomas. International Journal of Developmental Neuroscience, 1999, 17, 531-539.	1.6	30
248	Extraventricular cerebral anaplastic ependymomas. World Neurosurgery, 1999, 51, 630-635.	1.3	26
249	Indications for Repeat Surgery of Glioblastoma: Influence of Progress of Disease. , 1999, 33, 192-201.		12
250	Survival rates of malignant gliomas in Burgundy from 1990 to 1995. Neurological Research, 1999, 21, 171-174.	1.3	1
251	Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse. Journal of Clinical Oncology, 1999, 17, 2762-2762.	1.6	710
252	Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials. Journal of Clinical Oncology, 1999, 17, 2572-2572.	1.6	850
253	Clinical Cure of Glioblastoma. Neurologia Medico-Chirurgica, 2000, 40, 224-229.	2.2	19
254	Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magnetic Resonance in Medicine, 2000, 43, 845-853.	3.0	226
255	Biologic parameters that correlate with the prognosis of human gliomas. Neuropathology, 2000, 20, 176-183.	1.2	10
256	Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours. Neuropathology and Applied Neurobiology, 2000, 26, 76-90.	3.2	48

#	ARTICLE	IF	CITATIONS
257	Vascular Apoptosis and Involution in Gliomas Precede Neovascularization: A Novel Concept for Glioma Growth and Angiogenesis. <i>Laboratory Investigation</i> , 2000, 80, 837-849.	3.7	272
258	Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. <i>Journal of Neuro-Oncology</i> , 2000, 50, 121-137.	2.9	207
259	Chemotherapy for high-grade gliomas. <i>British Journal of Cancer</i> , 2000, 82, 1371-1380.	6.4	70
260	A comparative survival evaluation and assessment of interclassification concordance in adult supratentorial astrocytic tumors. <i>Pathology and Oncology Research</i> , 2000, 6, 46-52.	1.9	10
261	Flow Cytometric Characterization of Tumor-associated Macrophages in Experimental Gliomas. <i>Neurosurgery</i> , 2000, 46, 957-962.	1.1	203
262	A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. <i>British Journal of Cancer</i> , 2000, 83, 588-593.	6.4	1,154
263	Radical excision of intramedullary spinal cord tumors: surgical morbidity and long-term follow-up evaluation in 164 children and young adults. <i>Journal of Neurosurgery: Spine</i> , 2000, 93, 183-193.	1.7	175
264	Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. <i>Journal of Neurosurgery</i> , 2000, 93, 634-639.	1.6	62
265	Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. <i>Journal of the Neurological Sciences</i> , 2000, 175, 33-39.	0.6	93
267	Phase I and Pharmacokinetic Study of Photodynamic Therapy for High-Grade Gliomas Using a Novel Boronated Porphyrin. <i>Journal of Clinical Oncology</i> , 2001, 19, 519-524.	1.6	93
268	Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. <i>Annals of Oncology</i> , 2001, 12, 259-266.	1.2	333
269	Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. <i>Neuroradiology</i> , 2001, 43, 353-363.	2.2	89
271	Expression of Bcl-2, Bcl-x, and Bax proteins in astrocytomas in relation to patient survival. <i>Brain Tumor Pathology</i> , 2001, 18, 123-129.	1.7	4
272	Occludin expression in microvessels of neoplastic and non-neoplastic human brain. <i>Neuropathology and Applied Neurobiology</i> , 2001, 27, 384-395.	3.2	113
273	Role of microglia in glioma biology. <i>Microscopy Research and Technique</i> , 2001, 54, 106-113.	2.2	161
274	Genetic alterations and chemotherapeutic response in human diffuse gliomas. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 595-605.	2.4	21
275	Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 9480-9485.	7.1	130
276	A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. <i>Neuro-Oncology</i> , 2002, 4, 261-267.	1.2	92

#	ARTICLE	IF	CITATIONS
277	Microsatellite Analysis of Primary and Recurrent Glial Tumors Suggests Different Modalities of Clonal Evolution of Tumor Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 396-402.	1.7	15
278	Cell Proliferation and Tumors of the Central Nervous System Part 1: Evaluation of Mitotic Activity. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 501-509.	1.7	13
279	Imaging of intracranial tumours. <i>Imaging</i> , 2002, 14, 380-395.	0.0	1
280	High-Grade Gliomas and Solitary Metastases: Differentiation by Using Perfusion and Proton Spectroscopic MR Imaging. <i>Radiology</i> , 2002, 222, 715-721.	7.3	518
281	Intracranial Mass Lesions: Dynamic Contrast-enhanced Susceptibility-weighted Echo-planar Perfusion MR Imaging. <i>Radiology</i> , 2002, 223, 11-29.	7.3	482
282	The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine. <i>Neurosurgery</i> , 2002, 51, 343-357.	1.1	209
283	The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine. <i>Neurosurgery</i> , 2002, 51, 343-357.	1.1	406
284	Impact of Genotype and Morphology on the Prognosis of Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 321-328.	1.7	184
285	Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. <i>Journal of Clinical Oncology</i> , 2002, 20, 1375-1382.	1.6	394
286	Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. <i>Blood</i> , 2002, 100, 3484-3488.	1.4	1,617
287	Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. <i>Lancet Oncology</i> , The, 2002, 3, 557-564.	10.7	82
288	Anti-angiogenic agents for the treatment of brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002, 12, 477-499.	1.0	13
289	Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. <i>Journal of Clinical Oncology</i> , 2002, 20, 1375-1382.	1.6	703
290	Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study. <i>Oncology</i> , 2002, 63, 38-41.	1.9	55
291	The Psychiatric Manifestations of CNS Malignancies. , 0, , 335-339.		0
292	Dynamic susceptibility contrast-enhanced echo-planar imaging of cerebral gliomas. Effect of contrast medium extravasation. <i>Acta Radiologica</i> , 2002, 43, 354-359.	1.1	29
293	Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. <i>Journal of Magnetic Resonance Imaging</i> , 2002, 16, 407-422.	3.4	415
294	Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. <i>Glia</i> , 2002, 38, 329-338.	4.9	108

#	ARTICLE	IF	CITATIONS
295	Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells. <i>Glia</i> , 2002, 40, 44-54.	4.9	61
296	Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. <i>Neuroradiology</i> , 2002, 44, 656-666.	2.2	221
297	Telomerase as a therapeutic target for malignant gliomas. <i>Oncogene</i> , 2002, 21, 656-663.	5.9	78
298	Immunohistochemical markers for prognosis of cerebral glioblastomas. <i>Journal of Neuro-Oncology</i> , 2002, 58, 217-236.	2.9	31
299	Neuropathology and Molecular Genetics of Diffusely Infiltrating Cerebral Gliomas. <i>Medical Laser Application: International Journal for Laser Treatment and Research</i> , 2002, 17, 133-146.	0.3	2
300	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 62, 87-99.	2.9	16
301	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003, 65, 27-35.	2.9	222
302	Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. <i>Journal of Neuro-Oncology</i> , 2003, 62, 87-99.	2.9	122
303	Cerebral High-grade Astrocytoma (Glioblastoma) in a Cat. <i>Transboundary and Emerging Diseases</i> , 2003, 50, 269-271.	0.6	11
304	Salvage therapy in patients with glioblastoma. <i>Cancer</i> , 2003, 98, 2678-2686.	4.1	63
305	Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. <i>British Journal of Cancer</i> , 2003, 89, 2122-2132.	6.4	101
306	The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. <i>World Neurosurgery</i> , 2003, 60, 402-406.	1.3	46
307	Cortical dysplasia in extratemporal lobe intractable epilepsy: a study of 52 cases. <i>Annals of Diagnostic Pathology</i> , 2003, 7, 139-146.	1.3	30
308	Promising survival in patients with high-grade gliomas following therapy with a novel boronated porphyrin. <i>Journal of Clinical Neuroscience</i> , 2003, 10, 425-427.	1.5	33
309	Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality. <i>Journal of Immunology</i> , 2003, 171, 4927-4933.	0.8	81
310	Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. <i>Annals of Oncology</i> , 2003, 14, 603-614.	1.2	73
311	Recent developments in the molecular characterization and treatment of oligodendroglial tumors. <i>Neuro-Oncology</i> , 2003, 5, 128-138.	1.2	64
312	Could assessment of glioma methylene lipid resonance by ¹ H-MRS be of clinical value?. <i>British Journal of Radiology</i> , 2003, 76, 459-463.	2.2	44

#	ARTICLE	IF	CITATIONS
313	Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas. <i>Neurosurgery</i> , 2003, 53, 565-576.	1.1	64
314	Imaging Glioblastoma Multiforme. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 134-145.	2.0	91
315	Cell-Mediated Immunotherapy: A New Approach to the Treatment of Malignant Glioma. <i>Cancer Control</i> , 2003, 10, 138-147.	1.8	79
316	Morphology, Immunohistochemistry, and Genetic Alterations in Dog Astrocytomas. <i>Veterinary Pathology</i> , 2004, 41, 10-19.	1.7	101
317	Correlation of MR Perfusion Imaging and Vessel Tortuosity Parameters in Assessment of Intracranial Neoplasms. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 585-590.	1.9	36
318	Differentiating Surgical from Non-Surgical Lesions using Perfusion MR Imaging and Proton MR Spectroscopic Imaging. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 557-565.	1.9	44
319	Correlation of the response of recurrent malignant gliomas treated with interferon $\hat{I}\pm$ with tumor interferon $\hat{I}\pm$ gene content. <i>International Journal of Oncology</i> , 2004, 25, 419.	3.3	2
320	Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 700-707.	1.7	234
321	Development of novel targeted therapies in the treatment of malignant glioma. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 430-446.	46.4	214
322	Analysis of the activation status of Akt, NF $\hat{I}\pm$ B, and Stat3 in human diffuse gliomas. <i>Laboratory Investigation</i> , 2004, 84, 941-951.	3.7	196
323	Anaplastic astrocytoma: Diagnosis, prognosis, and management. <i>Seminars in Oncology</i> , 2004, 31, 618-634.	2.2	50
324	How does the immune system attack cancer?. <i>Current Problems in Surgery</i> , 2004, 41, 15-132.	1.1	14
325	Prognostic Limitations of the Daumas-Duport Grading Scheme in Infratentorial Neuroglial Tumors in Children. <i>Pediatric and Developmental Pathology</i> , 2004, 7, 138-147.	1.0	3
326	The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. <i>Neurosurgical Review</i> , 2004, 27, 58-64.	2.4	39
327	High grade gliomas. Multidisciplinary treatment with radiotherapy and concurrent carmustine after surgery. <i>Clinical and Translational Oncology</i> , 2004, 6, 207-211.	2.4	1
328	Boron and gadolinium neutron capture therapy. <i>Russian Chemical Bulletin</i> , 2004, 53, 1871-1888.	1.5	84
329	Analysis of variables affecting survival of patients with astracytomas. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2004, 16, 208-211.	2.2	0
330	Multicriteria fuzzy classification procedure PROCFTN: methodology and medical application. <i>Fuzzy Sets and Systems</i> , 2004, 141, 203-217.	2.7	37

#	ARTICLE	IF	CITATIONS
331	Survival analysis in patients with glioblastoma multiforme: Predictive value of choline-to-n-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. Journal of Magnetic Resonance Imaging, 2004, 19, 546-554.	3.4	182
332	Perfusion MRI of U87 brain tumors in a mouse model. Magnetic Resonance in Medicine, 2004, 51, 893-899.	3.0	64
333	Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1107-1115.	0.8	18
334	Gene Expression Profiling of Gliomas Strongly Predicts Survival. Cancer Research, 2004, 64, 6503-6510.	0.9	659
335	Post-Operative Sequential Chemo-Radiotherapy in High-Grade Cerebral Gliomas with Fotemustine. Journal of Chemotherapy, 2004, 16, 298-302.	1.5	5
336	MR Spectroscopy of Brain Tumors. Topics in Magnetic Resonance Imaging, 2004, 15, 291-313.	1.2	85
337	Magnetic Resonance Imaging Characteristics of a Gliosarcoma. The Neuroradiology Journal, 2005, 18, 59-63.	0.1	1
338	Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells. Oncology Reports, 2005, 13, 943.	2.6	9
339	Dendritic cell vaccines and immunity in glioma patients. Frontiers in Bioscience - Landmark, 2005, 10, 2861.	3.0	5
340	Update on brain tumor imaging. Current Neurology and Neuroscience Reports, 2005, 5, 169-177.	4.2	24
341	Cellular DNA content parameters as prognostic indicators in human astrocytomas. Journal of Neuro-Oncology, 2005, 71, 85-89.	2.9	6
342	The results of postoperative irradiation in malignant glioma patients. Reports of Practical Oncology and Radiotherapy, 2005, 10, 27-35.	0.6	0
343	Expression of hypoxia-inducible carbonic anhydrases in brain tumors. Neuro-Oncology, 2005, 7, 465-475.	1.2	84
344	Widespread CXCR4 Activation in Astrocytomas Revealed by Phospho-CXCR4-Specific Antibodies. Cancer Research, 2005, 65, 11392-11399.	0.9	100
345	OMICS and brain tumour biomarkers. British Journal of Neurosurgery, 2006, 20, 275-280.	0.8	19
346	Recent Advances in the Treatment of Malignant Astrocytoma. Journal of Clinical Oncology, 2006, 24, 1253-1265.	1.6	285
347	Phase II study of two-weekly temozolomide in patients with high-grade gliomas. Journal of Clinical Neuroscience, 2006, 13, 18-22.	1.5	11
348	Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales. World Neurosurgery, 2006, 66, 258-263.	1.3	27

#	ARTICLE	IF	CITATIONS
349	Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas. Journal of Korean Medical Science, 2006, 21, 739.	2.5	13
350	CNS Tumors. Topics in Magnetic Resonance Imaging, 2006, 17, 63-68.	1.2	9
351	New approaches to primary brain tumor treatment. Anti-Cancer Drugs, 2006, 17, 1003-1016.	1.4	45
352	Anaplastic Astrocytoma Presenting as Reversible Posterior Leukoencephalopathy Syndrome. Neurologist, 2006, 12, 311-313.	0.7	1
353	Comparison Between Contrast-enhanced Magnetic Resonance Imaging and Technetium 99m Glucohepatic Acid Single Photon Emission Computed Tomography With Histopathologic Correlation in Gliomas. Journal of Computer Assisted Tomography, 2006, 30, 723-733.	0.9	5
354	Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics, 2006, 6, 2924-2930.	2.2	27
355	Improving Morphology-Based Malignancy Grading Schemes in Astrocytic Tumors by Means of Computer-Assisted Techniques. Brain Pathology, 1998, 8, 29-38.	4.1	24
356	Supratentorial Pilocytic Astrocytomas, Astrocytomas, Anaplastic Astrocytomas and Glioblastomas are Characterized by a Differential Expression of S100 Proteins. Brain Pathology, 1999, 9, 1-19.	4.1	82
357	Molecular Classification of Human Diffuse Gliomas by Multidimensional Scaling Analysis of Gene Expression Profiles Parallels Morphology-Based Classification, Correlates with Survival, and Reveals Clinically Relevant Novel Glioma Subsets. Brain Pathology, 2002, 12, 108-116.	4.1	83
358	Angiogenesis in Gliomas: Biology and Molecular Pathophysiology. Brain Pathology, 2005, 15, 297-310.	4.1	298
359	Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. International Journal of Radiation Oncology Biology Physics, 2006, 64, 869-875.	0.8	32
360	Definition and Diagnostic Implications of Gemistocytic Astrocytomas: A Pathological Perspective. Journal of Neuro-Oncology, 2006, 76, 175-183.	2.9	33
361	Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation~.... Journal of Neuro-Oncology, 2006, 78, 295-302.	2.9	111
362	Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes. Journal of Neuro-Oncology, 2006, 79, 243-253.	2.9	13
363	Congenital gemistocytic astrocytoma in a fetus. Child's Nervous System, 2006, 22, 168-171.	1.1	11
364	Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. European Journal of Pharmacology, 2006, 542, 8-15.	3.5	38
365	Ionizing radiation induces astrocyte gliosis through microglia activation. Neurobiology of Disease, 2006, 21, 457-467.	4.4	179
366	Overexpression of IGFBP5, but not IGFBP3, Correlates with the Histologic Grade of Human Diffuse Glioma: A Tissue Microarray and Immunohistochemical Study. Technology in Cancer Research and Treatment, 2006, 5, 195-199.	1.9	34

#	ARTICLE	IF	CITATIONS
367	Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor- κ B Transcriptional Activity. <i>Clinical Cancer Research</i> , 2007, 13, 2178-2190.	7.0	37
368	Prognostic Significance of the Immunohistochemical Staining of Cleaved Caspase-3, an Activated Form of Caspase-3, in Gliomas. <i>Clinical Cancer Research</i> , 2007, 13, 3868-3874.	7.0	60
369	Pegylated Liposomal Doxorubicin in Recurrent Malignant Glioma: Analysis of a Case Series. <i>Oncology</i> , 2007, 72, 302-307.	1.9	28
370	High-Resolution Contrast-Enhanced, Susceptibility-Weighted MR Imaging at 3T in Patients with Brain Tumors: Correlation with Positron-Emission Tomography and Histopathologic Findings. <i>American Journal of Neuroradiology</i> , 2007, 28, 1280-1286.	2.4	63
371	Role of Perfusion CT in Glioma Grading and Comparison with Conventional MR Imaging Features. <i>American Journal of Neuroradiology</i> , 2007, 28, 1981-1987.	2.4	112
372	Human Glioblastoma U87MG Cells Transduced with a Dominant Negative p53 (TP53) Adenovirus Construct Undergo Radiation-Induced Mitotic Catastrophe. <i>Radiation Research</i> , 2007, 168, 183-192.	1.5	16
373	Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13122-13127.	7.1	49
374	Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. <i>World Neurosurgery</i> , 2007, 68, 250-254.	1.3	19
375	High grade glioma: Imaging combined with pathological grade defines management and predicts prognosis. <i>Radiotherapy and Oncology</i> , 2007, 85, 371-378.	0.6	41
376	Molecular Pathogenesis of Adult Brain Tumors and the Role of Stem Cells. <i>Neurologic Clinics</i> , 2007, 25, 891-924.	1.8	34
377	Inhibition of angiogenesis and invasion in malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1537-1560.	2.4	50
378	Increased phosphorylation of caveolin-1 in the spinal cord of irradiated rats. <i>Journal of Veterinary Science</i> , 2007, 8, 323.	1.3	5
379	Vascular endothelial growth factor in astrogloma stem cell biology and response to therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 111-125.	3.6	26
380	Prognostic factors for anaplastic astrocytomas. <i>Journal of Neuro-Oncology</i> , 2007, 81, 295-303.	2.9	33
381	Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 88, 11-17.	2.9	46
382	Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 425-439.	4.2	125
383	Revisiting anaplastic astrocytomas I: An expansive growth pattern is associated with a better prognosis. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 1311-1321.	3.4	12
384	Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal <i>in vivo</i> and <i>ex vivo</i> study. <i>NMR in Biomedicine</i> , 2008, 21, 1043-1056.	2.8	98

#	ARTICLE	IF	CITATIONS
385	External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma. <i>Cancer</i> , 2008, 113, 559-565.	4.1	4
386	Treatment of Glioblastoma Multiforme by Stereotactic Radio Therapy/Intensity Modulated Radiation Therapy. <i>Apollo Medicine</i> , 2008, 5, 223-227.	0.0	0
387	The Role of Fascin in the Migration and Invasiveness of Malignant Glioma Cells. <i>Neoplasia</i> , 2008, 10, 149-159.	5.3	83
388	Survival following CyberKnife Radiosurgery and Hypofractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 249-255.	1.9	25
389	In Vivo Differentiation of Aerobic Brain Abscesses and Necrotic Glioblastomas Multiforme Using Proton MR Spectroscopic Imaging. <i>American Journal of Neuroradiology</i> , 2008, 29, 1511-1518.	2.4	34
390	Regulatory effect of nerve growth factor in $\alpha 1$ integrin-dependent progression of glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 968-980.	1.2	51
391	Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. <i>Radiology</i> , 2008, 247, 490-498.	7.3	466
392	Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. <i>Journal of Neurosurgery</i> , 2008, 108, 330-335.	1.6	9
393	<i>Review:</i> Intracavitary Radioimmunotherapy to Treat Solid Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 92-107.	1.0	22
394	5 Anatomic Imaging. , 2008, , .		0
395	Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2008, 1, 3-13.	0.9	4
396	Dynamic Contrast-Enhanced Derived Cerebral Blood Volume Correlates Better With Leak Correction Than With No Correction for Vascular Endothelial Growth Factor, Microvascular Density, and Grading of Astrocytoma. <i>Journal of Computer Assisted Tomography</i> , 2008, 32, 955-965.	0.9	34
397	Long-Term Outcome of Postoperative Irradiation in Patients with Newly Diagnosed WHO Grade III Anaplastic Gliomas. <i>Tumori</i> , 2009, 95, 317-324.	1.1	10
398	Perfusion MR imaging in adult neoplasia. , 0, , 341-368.		0
399	Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NF- κ B activation in glioblastoma. <i>Neuro-Oncology</i> , 2009, 11, 132-141.	1.2	13
400	Molecular Advances of Brain Tumors in Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2009, 19, 171-178.	2.2	56
401	Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. <i>Journal of Neuro-Oncology</i> , 2009, 91, 69-81.	2.9	142
403	Characterization of Tumor Angiogenesis in Rat Brain Using Iron-Based Vessel Size Index MRI in Combination with Gadolinium-Based Dynamic Contrast-Enhanced MRI. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1714-1726.	4.3	65

#	ARTICLE	IF	CITATIONS
404	Neuroimaging in Neuro-Oncology. Neurotherapeutics, 2009, 6, 465-477.	4.4	130
405	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15
406	Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas. Journal of Clinical Neuroscience, 2009, 16, 1119-1130.	1.5	98
407	New drugs for brain tumors? Insights from chemical probing of neural stem cells. Medical Hypotheses, 2009, 72, 683-687.	1.5	28
408	Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opinion on Investigational Drugs, 2009, 18, 1061-1083.	4.1	432
409	Glioblastoma multiforme: a review of therapeutic targets. Expert Opinion on Therapeutic Targets, 2009, 13, 701-718.	3.4	138
410	Mechanisms of Brain Tumor Angiogenesis. , 2009, , 461-506.		0
411	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Review of Neurotherapeutics, 2009, 9, 1815-1836.	2.8	39
412	Targeted Therapies for Malignant Brain Tumors. , 2009, , 475-519.		0
413	The Guanine Nucleotide Exchange Factor SWAP-70 Modulates the Migration and Invasiveness of Human Malignant Glioma Cells. Translational Oncology, 2009, 2, 300-IN1.	3.7	22
414	Clinical Application of MR Spectroscopy and Imaging of Brain Tumor. Magnetic Resonance in Medical Sciences, 2010, 9, 167-175.	2.0	36
415	Imaging of adult astrocytic brain tumours with 7 T MRI: preliminary results. European Radiology, 2010, 20, 704-713.	4.5	53
416	Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. European Radiology, 2010, 20, 2482-2490.	4.5	48
417	Ex vivo and in vivo diagnosis of C6 glioblastoma development by Raman spectroscopy coupled to a microprobe. Analytical and Bioanalytical Chemistry, 2010, 398, 477-487.	3.7	68
418	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 2010, 120, 707-718.	7.7	719
419	HIF-1 α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer, 2010, 10, 605.	2.6	85
420	Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. Journal of Magnetic Resonance Imaging, 2010, 32, 803-808.	3.4	37
421	The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmacogenomics and Personalized Medicine, 2010, 3, 111.	0.7	17

#	ARTICLE	IF	CITATIONS
422	New developments in the medicinal chemistry of carboranes. Collection of Czechoslovak Chemical Communications, 2010, 75, 995-1022.	1.0	41
423	Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis. Journal of Neurosurgery, 2010, 112, 1020-1032.	1.6	39
424	Solitary metastases and high-grade gliomas: radiological differentiation by morphometric analysis and perfusion-weighted MRI. Clinical Radiology, 2010, 65, 15-20.	1.1	64
425	RNA interference therapy for glioblastoma. Expert Opinion on Biological Therapy, 2010, 10, 927-936.	3.1	26
426	Clinical pitfalls related to short and long echo times in cerebral MR spectroscopy. Journal of Neuroradiology, 2011, 38, 69-75.	1.1	17
427	8 Imaging of Brain Cancer. , 2011, , 127-146.		0
428	Epidemiology, Histologic Classification, and Clinical Course of Brain Tumors. , 2011, , 1-12.		2
429	Pediatric Tumors. , 2011, , 285-332.		1
430	Migration and Invasion of Brain Tumors. , 0, , .		0
431	Intracranial anaplastic astrocytoma in a 19-week-old boxer dog. Journal of Small Animal Practice, 2011, 52, 325-328.	1.2	7
432	Brain volume perfusion CT performed with 128-detector row CT system in patients with cerebral gliomas: A feasibility study. European Radiology, 2011, 21, 1811-1819.	4.5	22
433	Two-year survival of low-grade and high-grade glioma patients using data from the Swedish Cancer Registry. Acta Neurochirurgica, 2011, 153, 467-471.	1.7	10
434	Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 441-450.	6.4	71
435	Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models. Bulletin of Mathematical Biology, 2011, 73, 2-32.	1.9	330
436	Classification and pathogenesis of brain tumors. , 2012, , 36-58.		2
437	Inhibiting angiogenesis in malignant gliomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 279-308.	1.8	1
438	â€œTumoral Pseudoblastsâ€• Identified within Gliomas at High-Spatial-Resolution Ultrahigh-Field-Strength Gradient-Echo MR Imaging Corresponds to Microvasculature at Stereotactic Biopsy. Radiology, 2012, 264, 210-217.	7.3	23
439	NF-ÎB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31, 251-264.	5.9	37

#	ARTICLE	IF	CITATIONS
440	Pathology: Commonly Monitored Glioblastoma Markers: EGFR, EGFRvIII, PTEN, and MGMT. Neurosurgery Clinics of North America, 2012, 23, 237-246.	1.7	24
441	Characterization of Immune Cell Infiltration Into Canine Intracranial Meningiomas. Veterinary Pathology, 2012, 49, 784-795.	1.7	22
442	Molecular imaging of cancer: MR spectroscopy and beyond. European Journal of Radiology, 2012, 81, 566-577.	2.6	65
443	Primary human glioblastomas – prognostic value of clinical and histopathological parameters. , 2012, 31, 361-368.		12
444	Heterogeneity of cancer-initiating cells within glioblastoma. Frontiers in Bioscience - Scholar, 2012, S4, 1235-1248.	2.1	19
445	Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clinical Pharmacology: Advances and Applications, 2013, 5, 1.	1.2	36
446	Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging, 2012, 12, 423-436.	2.8	125
447	In vivo imaging of vessel diameter, size, and density: A comparative study between MRI and histology. Magnetic Resonance in Medicine, 2013, 69, 18-26.	3.0	59
449	Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent. Biomedicine and Pharmacotherapy, 2013, 67, 451-457.	5.6	30
450	The prognosis of anaplastic astrocytoma with radiologic necrosis mimicking glioblastoma. British Journal of Neurosurgery, 2013, 27, 74-79.	0.8	2
451	Potential of MR spectroscopy for assessment of glioma grading. Clinical Neurology and Neurosurgery, 2013, 115, 146-153.	1.4	172
452	Brain Cancer: Evidence-Based Neuroimaging. , 2013, , 419-438.		0
453	The Molecular Pathology of Primary Brain Tumors. , 2013, 18, 210-220.		0
454	Brain Tumor Genomics. , 2014, , 321-338.		0
456	Sports and childhood brain tumors: Can I play?. Neuro-Oncology Practice, 2014, 1, 158-165.	1.6	2
457	Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1 α accumulation. Nature Cell Biology, 2014, 16, 445-456.	10.3	83
458	Glioblastoma-arteriovenous fistula complex: imaging characteristics and treatment considerations. Clinical Imaging, 2014, 38, 187-190.	1.5	5
459	Downregulation of programmed cell death 10 is associated with tumor cell proliferation, hyperangiogenesis and peritumoral edema in human glioblastoma. BMC Cancer, 2015, 15, 759.	2.6	22

#	ARTICLE	IF	CITATIONS
460	Brain Tumor Clinical Trials. Neurosurgery, 2015, 62, 141-145.	1.1	0
461	Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced MR in Tumor Parenchyma and Peritumoral Area for Distinction of Brain Tumors. PLoS ONE, 2015, 10, e0138573.	2.5	39
462	Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients. BioMed Research International, 2015, 2015, 1-13.	1.9	6
463	Choosing Wisely. Neurosurgery, 2015, 76, 1-6.	1.1	23
464	The role of neuropathology in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 531-549.	2.9	120
465	Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme. Journal of Clinical Neuroscience, 2015, 22, 1802-1808.	1.5	4
466	Treatment by specialist surgical neurooncologists improves survival times for patients with malignant glioma. Journal of Neurosurgery, 2015, 122, 297-302.	1.6	33
467	Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations. Computational and Mathematical Methods in Medicine, 2016, 2016, 1-11.	1.3	7
468	Global Changes in Lipid Profiles of Mouse Cortex, Hippocampus, and Hypothalamus Upon p53 Knockout. Scientific Reports, 2016, 6, 36510.	3.3	11
469	Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma. Journal of Neuro-Oncology, 2016, 126, 463-472.	2.9	21
470	Craniospinal irradiation with concomitant and adjuvant temozolomideâ€”a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. Journal of Neuro-Oncology, 2016, 127, 295-302.	2.9	8
471	Magnetic resonance imaging biomarkers for clinical routine assessment of microvascular architecture in glioma. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 632-643.	4.3	35
472	Quantitative glioma grading using transformed gray-scale invariant textures of MRI. Computers in Biology and Medicine, 2017, 83, 102-108.	7.0	56
473	Effects of quercetin on proliferation and migration of human glioblastoma U251 cells. Biomedicine and Pharmacotherapy, 2017, 92, 33-38.	5.6	76
474	Citation classics in neuro-oncology: assessment of historical trends and scientific progress. Neuro-Oncology, 2017, 19, 1158-1172.	1.2	24
475	Development of induced glioblastoma by implantation of a human xenograft in Yucatan minipig as a large animal model. Journal of Neuroscience Methods, 2017, 282, 61-68.	2.5	25
476	Quantitative analysis of permeability for glioma grading using dynamic contrast-enhanced magnetic resonance imaging. Oncology Letters, 2017, 14, 5418-5426.	1.8	25
477	Brain tumor segmentation using holistically nested neural networks in MRI images. Medical Physics, 2017, 44, 5234-5243.	3.0	79

#	ARTICLE	IF	CITATIONS
478	Grading of diffuse astrocytic gliomas: Broders, Kernohan, ZÃ¼lch, the WHOâ€ and Shakespeare. Acta Neuropathologica, 2017, 134, 517-520.	7.7	15
479	Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes. BMC Cancer, 2017, 17, 424.	2.6	4
480	Computer-aided grading of gliomas based on local and global MRI features. Computer Methods and Programs in Biomedicine, 2017, 139, 31-38.	4.7	69
481	Low concentration of quercetin antagonizes the invasion and angiogenesis of human glioblastoma U251 cells. OncoTargets and Therapy, 2017, Volume 10, 4023-4028.	2.0	45
482	Classifying Glioblastoma Multiforme Follow-Up Progressive vs. Responsive Forms Using Multi-Parametric MRI Features. Frontiers in Neuroscience, 2016, 10, 615.	2.8	22
483	Effect of a computer-aided diagnosis system on radiologists' performance in grading gliomas with MRI. PLoS ONE, 2017, 12, e0171342.	2.5	16
484	The Apparent Diffusion Coefficient in Glial Tumors. OMICS Journal of Radiology, 2017, 06, .	0.0	0
485	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
486	Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Pathology Research and Practice, 2018, 214, 881-888.	2.3	33
488	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. Seminars in Neurology, 2018, 38, 019-023.	1.4	30
489	Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. Seminars in Oncology Nursing, 2018, 34, 430-442.	1.5	5
490	Image-Guided Neutron Capture Therapy Using the Gd-DO3A-BTA Complex as a New Combinatorial Treatment Approach. Contrast Media and Molecular Imaging, 2018, 2018, 1-9.	0.8	13
491	A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients. Cellular Physiology and Biochemistry, 2018, 48, 1755-1770.	1.6	34
492	Improved survival of Swedish glioblastoma patients treated according to Stupp. Acta Neurologica Scandinavica, 2018, 138, 332-337.	2.1	16
493	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. , 2019, , .		0
494	The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathologica Communications, 2019, 7, 156.	5.2	47
495	Glioblastoma and Anaplastic Astrocytoma: Differentiation Using MRI Texture Analysis. Frontiers in Oncology, 2019, 9, 876.	2.8	23
496	Glioblastoma cancer stem cell biology: Potential theranostic targets. Drug Resistance Updates, 2019, 42, 35-45.	14.4	115

#	ARTICLE	IF	CITATIONS
497	Intelligent Glioma Grading Based on Deep Transfer Learning of MRI Radiomic Features. Applied Sciences (Switzerland), 2019, 9, 4926.	2.5	13
498	Apoptosis related microRNAs and MGMT in glioblastoma cell lines submitted to treatments with ionizing radiation and temozolomide. Reports of Practical Oncology and Radiotherapy, 2020, 25, 714-719.	0.6	3
499	^{67}Cu drives epithelial differentiation in glioma. Clinical and Translational Medicine, 2020, 10, e165.	4.0	1
500	Approaches to PET Imaging of Glioblastoma. Molecules, 2020, 25, 568.	3.8	42
501	Analysis of the P53N a Novel Protein Encoded on Chromosome 22q12.1-12.3 in Glioblastomas and Ependymomas Specimens. Journal of Molecular Neuroscience, 2021, 71, 1714-1722.	2.3	0
502	Bibliometric analysis of the top 100 most-cited articles on astrocytoma. , 2021, 12, 62.		2
503	Gemistocytes in newly diagnosed glioblastoma multiforme: Clinical significance and practical implications in the modern era. Journal of Clinical Neuroscience, 2021, 88, 120-127.	1.5	2
504	Joint application of biochemical markers and imaging techniques in the accurate and early detection of glioblastoma. Pathology Research and Practice, 2021, 224, 153528.	2.3	1
505	The multifaceted PDCD10/CCM3 gene. Genes and Diseases, 2021, 8, 798-813.	3.4	20
506	Differentiation between Glioblastoma and Solitary Metastasis: Morphologic Assessment by Conventional Brain MR Imaging and Diffusion-Weighted Imaging. Investigative Magnetic Resonance Imaging, 2021, 25, 23.	0.4	6
507	Anti-angiogenic Chemotherapy in Central Nervous System Tumors. Cancer Treatment and Research, 2004, 117, 337-349.	0.5	19
508	Current Concepts of the Histopathological Classification of Tumours of the Central Nervous System. , 1995, , 29-108.		2
509	Boron Neutron Capture Therapy (BNCT) of F98 Glioma Bearing Rats Using Boronophenylalanine (BPA) as a Capture Agent. , 1993, , 551-555.		2
510	Blood-Brain Barrier Disruption in the Treatment of Brain Tumors. , 1989, , 195-261.		27
511	Angiogenesis in human gliomas: Prognostic and therapeutic implications. Exs, 1997, 79, 29-46.	1.4	8
512	Strahlentherapie mit negativen Pi-Mesonen. , 1987, , 146-165.		4
513	Geschwülste des zentralen und peripheren Nervensystems. Spezielle Pathologische Anatomie, 1988, , 215-542.	0.0	3
514	Epidemiology, Histologic Classification and Clinical Course of Brain Tumors. , 2002, , 1-10.		2

#	ARTICLE	IF	CITATIONS
515	Histoprognosis of Gliomas. Advances and Technical Standards in Neurosurgery, 1994, 21, 43-76.	0.5	6
516	Pathology of Human Intracranial Neoplasia. , 1987, , 1-90.		16
517	Results of Chemotherapy of Malignant Brain Tumors in Adults. , 1987, , 349-395.		9
518	Prospective Analysis of Grade III and IV Gliomas, With Considerations on Histological Classification. (An E.O.R.T.C. Brain Tumor Group Study). , 1987, , 237-242.		2
519	Findings of Aberrant Epidermal Growth Factor Receptor in Primary Human Malignant Gliomas. , 1991, , 101-103.		1
520	Prognostic Factors in Anaplastic Astrocytomas after Surgery and Conventional Radiotherapy. , 1991, , 179-180.		1
521	Genetics of Astrocytic Tumor Progression. , 1993, 3, 69-94.		3
522	Anaplastic Astrocytoma. , 2005, , 122-142.		1
523	Imaging of Tumors in Epilepsy. , 1999, , 315-335.		1
524	Brain Tumor Outcome Studies. , 2011, , 1243-1253.		1
525	Pathologic Analysis of Primary Brain Tumors. Neurologic Clinics, 1985, 3, 711-728.	1.8	38
526	Concurrent Radiation and Intracarotid Cisplatin Infusion in Malignant Gliomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 138-142.	1.3	12
527	Expression of Vascular Endothelial Growth Factor and Its Receptors in the Anaplastic Progression of Astrocytoma, Oligodendroglioma, and Ependymoma. American Journal of Surgical Pathology, 1998, 22, 816-826.	3.7	161
528	Low-grade Glial Tumors in Basal Ganglia and Thalamus. Neurosurgery, 1994, 35, 817-821.	1.1	5
529	Aberrant p53 Expression Does Not Correlate with the Prognosis in Anaplastic Astrocytoma. Neurosurgery, 1995, 37, 246-254.	1.1	3
530	Effects of Iodine-125 Brachytherapy on the Proliferative Capacity and Histopathological Features of Glioblastoma Recurring after Initial Therapy. Neurosurgery, 1997, 40, 910-918.	1.1	19
531	Tumours. , 2008, , 1821-2000.		6
532	Regulatory effect of nerve growth factor in $\alpha 9 \beta 1$ integrin-dependent progression of glioblastoma. Neuro-Oncology, 2008, 10, 968-980.	1.2	31

#	ARTICLE	IF	CITATIONS
533	Receptor Tyrosine Kinase Expression in Astrocytic Lesions. Neurosurgery, 1993, 33, 106-115.	1.1	31
534	Low-Grade Astrocytomas May Arise from Different Astrocyte Lineages. Neurosurgery, 1993, 33, 627-632.	1.1	42
535	The Limited Value of Cytoreductive Surgery in Elderly Patients with Malignant Gliomas. Neurosurgery, 1994, 34, 62-67.	1.1	50
536	Histological Characteristics and Expression of Acidic and Basic Fibroblast Growth Factor Genes in Intracerebral Xenogeneic Transplants of Human Glioma Cells. Neurosurgery, 1994, 34, 136-143.	1.1	22
537	Prognostic Significance of Ki-67 Proliferation Index in Supratentorial Fibrillary Astrocytic Neoplasms. Neurosurgery, 1994, 34, 674-679.	1.1	96
538	Prognostic Significance of Flow Cytometry Deoxyribonucleic Acid Analysis of Human Oligodendrogliomas. Neurosurgery, 1994, 34, 680-687.	1.1	25
539	Flow Cytometric Characterization of Tumor-associated Macrophages in Experimental Gliomas. Neurosurgery, 2000, 46, 957-962.	1.1	162
540	Diagnostic markers for glioblastoma. Histology and Histopathology, 2011, 26, 1327-41.	0.7	16
541	Pediatric Cerebellar Hemorrhagic Glioblastoma Multiforme. Open Neuroimaging Journal, 2012, 6, 13-15.	0.2	4
542	Vascular architecture mapping for early detection of glioblastoma recurrence. Neurosurgical Focus, 2019, 47, E14.	2.3	16
543	Gamma-ray irradiation stimulates the expression of caveolin-1 and GFAP in rat spinal cord: a study of immunoblot and immunohistochemistry. Journal of Veterinary Science, 2006, 7, 309.	1.3	11
544	Do Cancer Stem Cells have an Immunomodulatory Role Different from the Bulk of Tumor Cells?. Journal of Carcinogenesis & Mutagenesis, 2013, S14, .	0.3	5
545	The Histopathological Spectrum of Primary Human Glioblastomas with Relations to Tumour Biology. , 2012, 02, .		3
546	Evaluation of Epithelial and Keratin Markers in Glioblastoma Multiforme. Archives of Pathology and Laboratory Medicine, 1999, 123, 917-920.	2.5	52
547	Prognostic Factors for Long-Term Survival after Glioblastoma. , 2008, 12, 45-48.		124
548	Neuro-oncology. , 2003, , 269-312.		0
549	Chemotherapy in Adult CNS Tumors. Medical Radiology, 2003, , 437-448.	0.1	0
550	Imaging of Intracranial and Spinal Neoplasms. Medical Radiology, 2003, , 109-144.	0.1	1

#	ARTICLE	IF	CITATIONS
551	Common histological patterns and cell types of tumors. , 2005, , 3-62.		0
552	Common histological patterns and cell types of tumors. , 2005, , 17-76.		0
553	Vaccines and Beneficial Immunity in Glioma Patients. , 2006, , 265-291.		0
555	Perfusion Imaging: Physical Principles and Applications in the Brain. , 2008, , 273-308.		0
556	Tumors of the Brain and Spinal Cord. , 2009, , 601-720.		2
557	Intracranial Neoplasms. , 2009, , 49-144.		3
558	Imaging of Brain Neoplasm. , 2010, , 103-114.		0
559	General Care of Patients with Cancer Involving the Central Nervous System. , 2010, , 771-781.		1
560	Immunohistochemical expression of cyclooxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival. Turkish Neurosurgery, 2010, , .	0.2	8
561	Multifocal Glioblastoma Multiforme. Electronic Journal of General Medicine, 2012, 9, 289-291.	0.7	0
562	Relationship between Histopathological Subtypes of Intracranial Astrocytoma Patients. Bangladesh Journal of Neuroscience, 2014, 27, 87-93.	0.1	0
564	Tumors of the Central Nervous System (II). , 1988, , 127-312.		1
565	Intraarterial Chemotherapy of WHO Grade IV Cerebral Gliomas with the Nitrosourea Derivate 1-(4-Amino-2-Methyl-5-Pyrimidinyl)-Methyl- (2-Chlorethyl)-3-Nitrosourea (ACNU). , 1989, , 533-536.		0
566	Recessive Mutations in Human Cancer Progression. , 1991, , 163-171.		0
567	Zur Spontanprognose zerebraler Tumoren. Verhandlungen Der Deutschen Gesellschaft FÃ¼r Neurologie, 1991, , 292-293.	0.0	0
568	The Problems of Pathological Diagnosis. , 1991, , 17-36.		1
569	Recessive Mutations in Cancer Predisposition and Progression. , 1991, 57, 171-181.		2
570	GENETICS OF TUMOR PROGRESSION. , 1992, , 398-406.		0

#	ARTICLE	IF	CITATIONS
571	Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro. , 1994, , 63-73.		10
572	Prognostic Significance of Flow Cytometry Deoxyribonucleic Acid Analysis of Human Astrocytomas. Neurosurgery, 1994, 35, 119-126.	1.1	2
573	Evaluation of Histological Grading Systems of Astrocytic Tumors. , 1996, , 39-44.		0
574	A Phase I Study of an Anti-epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant Gliomas. Neurosurgery, 1996, 39, 478-483.	1.1	53
575	Non-Curative Neurosurgery for Malignant Brain Tumours. Focus on Cancer, 1998, , 71-82.	0.1	0
576	Evaluation of Nimustine Hydrochloride/Etoposide Combination Chemotherapy for Malignant Gliomas : Part 1 A Statistical Study using Cox's Proportional Hazard Model. Japanese Journal of Neurosurgery, 1999, 8, 583-590.	0.0	0
577	Gliale Neoplasien. , 1999, , 450-509.		0
578	Anaplastic Astrocytoma. , 2016, , 14-21.		0
579	Anaplastic Astrocytoma. , 2016, , 438-441.		0
580	MRI EVALUATION OF SUPRATENTORIAL TUMOURS. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 141-147.	0.1	0
581	3.0T Imaging of Brain Gliomas. , 2017, , 271-319.		0
582	DIAGNOSTIC ABILITY OF MRI IN CHARACTERISATION OF SUPRATENTORIAL BRAIN TUMOURS. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 2056-2061.	0.0	0
584	Magnetic Resonance Imaging in Evaluation of Supratentorial Tumours. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 637-641.	0.0	0
587	Histologic Classification of High-Grade Gliomas. , 2007, , 3-35.		0
588	Molecular Classifications. , 2007, , 37-42.		1
589	Irradiation and CCNU in Glioma Therapy. Journal of Neurosurgery, 1989, 71, 791-3.	1.6	1
590	Angiogenic growth factors in neural embryogenesis and neoplasia. American Journal of Pathology, 1995, 146, 293-309.	3.8	67
591	Dual lineage of astrocytomas. American Journal of Pathology, 1989, 135, 517-27.	3.8	45

#	ARTICLE	IF	CITATIONS
592	Uniform lineage of oligodendrogliomas. American Journal of Pathology, 1989, 135, 529-40.	3.8	54
593	Susceptibility-based imaging of glioblastoma microvasculature at 8 T: correlation of MR imaging and postmortem pathology. American Journal of Neuroradiology, 2004, 25, 756-60.	2.4	35
594	Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. American Journal of Neuroradiology, 2001, 22, 1109-16.	2.4	124
595	Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. American Journal of Neuroradiology, 2004, 25, 1524-32.	2.4	156
596	Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. American Journal of Neuroradiology, 2000, 21, 881-90.	2.4	101
597	Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. American Journal of Neuroradiology, 2006, 27, 859-67.	2.4	499
598	Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. American Journal of Neuroradiology, 2003, 24, 1989-98.	2.4	815
599	Synthesis of MIL-Modified Fe ₃ O ₄ Magnetic Nanoparticles for Enhancing Uptake and Efficiency of Temozolomide in Glioblastoma Treatment. International Journal of Molecular Sciences, 2022, 23, 2874.	4.1	12
603	Molecular biology of glioma tumorigenesis. Histology and Histopathology, 2003, 18, 207-16.	0.7	41
604	A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma. Current Medical Science, 2022, 42, 650-657.	1.8	3
607	RADIOLOGIC DIAGNOSIS, STAGING, AND FOLLOW-UP OF ADULT CENTRAL NERVOUS SYSTEM PRIMARY MALIGNANT GLIOMA. Radiologic Clinics of North America, 1994, 32, 183-196.	1.8	9
608	Differentiation of Intracerebral Tumor Entities with Quantitative Contrast Attenuation and Iodine Mapping in Dual-Layer Computed Tomography. Diagnostics, 2022, 12, 2494.	2.6	1
610	Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. Science Translational Medicine, 2023, 15, .	12.4	10
611	Value of MRI in Brain Ring enhancing lesions. Kufa Journal for Nursing Sciences, 2014, 3, 40-49.	0.1	0
612	Treatment with quercetin increases Nrf2 expression and neuronal differentiation of sub ventricular zone derived neural progenitor stem cells in adult rats. Molecular Biology Reports, 2023, 50, 8163-8175.	2.3	1